Keep in touch

Sub-Licensees

Cipla

Sub-licence covering: dolutegravir (DTG)

In JUly 2014, the MPP signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir for paediatrics and adults use.

 

Desano

Sub-licence covering: atazanavir (ATV)

In May 2014, the MPP signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano.

 

Micro Labs

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP signed a sublicensing agreement with Micro Labs allowing it to manufacture to manufacture dolutegravir for both adult and paediatric treatment.

Mylan

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP signed a sublicensing agreement with Mylan allowing it to manufacture to manufacture dolutegravir for both adult and paediatric use.

Shilpa Medicare

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In June 2013, the MPP, Shilpa Medicare and Gilead signed a sublicensing agreement allowing it to manufacture five key HIV medicines licensed to the MPP by Gilead Sciences in July 2011.

Aurobindo Pharma Limited

Sub-licences covering: abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In July 2014, the MPP, Aurobindo and Bristol Myers-Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir for paediatric use in the 118 countries where 98.7% of children living with HIV reside. In October 2011, the MPP signed a sublicensing agreement with key generics manufacturer Aurobindo covering FTC, COBI, EVG, and the Quad. Aurobindo chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.

Shasun Pharma Solutions

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

On 25 February 2013, the MPP signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Shasun Pharma Solutions.

Laurus Labs

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG] and dolutegravir (DTG)

In July 2014, the MPP signed a new sublicensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

On 26 September 2012, the MPP signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Laurus Labs.

Hetero Labs

Sub-licences covering: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In July 2012, the MPP signed a sublicensing agreement with leading generic ARV manufacturer Hetero. Hetero, like Aurobindo and Emcure, chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.

Emcure Pharmaceuticals Limited

Sub-licences covering: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

In July 2014, the MPP and Bristol Myers-Squipp signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV)

In January 2012, the MPP signed a sublicensing agreement with key generics manufacturer Emcure. Emcure, like Aurobindo, chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.

This page is also available in: French, Spanish